Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
Rhea-AI Summary
Precipio (NASDAQ: PRPO) is urging shareholders to instruct their brokers to vote their shares immediately for the 2026 annual shareholders meeting. Votes must be received by 11:59 p.m. ET on June 14, 2026 for the meeting scheduled on June 15, 2026.
About 42% of shares have been voted; at least 50% is required to reach quorum. According to Precipio, failure to reach quorum could force an adjournment and reconvening of the meeting, leading to high additional costs.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- Risk of high additional costs if quorum is not reached and meeting is adjourned
Key Figures
Market Reality Check
Peers on Argus
Pre-news, PRPO was up 0.35% with light volume while peers were mixed: NOTV down 6%, PRPH down 9.82%, BIAF up 7.95%, and ISPC up 0.73%. Only one peer appeared in the momentum scanner, pointing to stock-specific rather than broad sector dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 14 | Q1 2026 earnings | Neutral | -8.9% | Reported higher revenue but continued net loss and negative earnings reaction. |
| May 13 | Management options vesting | Neutral | -0.3% | Disclosure of large share-price gain driving 2025 option vesting and stock comp expense. |
| May 06 | Q1 call announcement | Neutral | +1.4% | Announced Q1-2026 shareholder update call with first-time moderated live Q&A. |
| Mar 12 | Year-end call notice | Neutral | -6.7% | Scheduled Q4 and year-end 2025 shareholder update call and replay details. |
| Mar 10 | Clinical assay study | Positive | +3.3% | Published joint study validating Bloodhound BCR::ABL1 assay with high sensitivity. |
Recent news has been followed by moves largely aligned with the tone: clinical validation and shareholder communications saw modest gains, while earnings and governance/insider-related items often coincided with declines.
Over the last six months, PRPO has blended operational, clinical, and governance updates. Q1 2026 results on May 14 showed revenue growth but ongoing losses and drew a -8.95% reaction. A day earlier, disclosure of 2025 market-based option vesting and a related $800,000 non-cash expense saw a near-flat move. Multiple shareholder update calls on March 12 and May 6 produced modest, mixed reactions. In contrast, the March 10 joint study on the Bloodhound BCR::ABL1 assay and its sensitivity to 0.001% coincided with a positive price response.
Market Pulse Summary
This announcement emphasizes the need for shareholders and brokers to submit voting instructions so at least 50% of shares are voted and a quorum is reached for the June 15, 2026 Annual Meeting. Only 42% had been voted at the time of the release, and management seeks to avoid the added expense of adjournment. In context of prior filings noting ongoing losses, investors may watch how governance decisions and board elections support the company’s longer-term strategic and financial plans.
Key Terms
quorum regulatory
AI-generated analysis. Not financial advice.
NEW HAVEN, Conn., June 12, 2026 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately. Votes must be received by 11:59 p.m., Eastern Time, on June 14, 2026, to be voted at the Annual Meeting.
In order to ensure that there is a quorum required for the shareholders’ meeting that is scheduled to take place tomorrow, June 15, 2026, at 10 a.m. Eastern Time.
At the time of this press release, approximately
If the Company does not receive sufficient votes to establish a quorum, it may need to adjourn and reconvene the shareholder meeting, which would result in high additional costs. Management would like to avoid these additional costs. Whether you intend to vote for or against the proposals, please submit your voting instructions to your broker so that your shares may be counted toward quorum and a potential adjournment may be avoided.
About Precipio
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.
Availability of Other Information About Precipio
For more information, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx) and LinkedIn (Precipio) and on Facebook. Investors and others should note that we communicate with our investors and the public using our company website (https://www.precipiodx.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing.
Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Inquiries: investors@precipiodx.com +1-203-787-7888 Ext. 523